Ancora Advisors LLC cut its position in Nutex Health Inc. (NASDAQ:NUTX - Free Report) by 57.0% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 18,086 shares of the company's stock after selling 23,998 shares during the quarter. Ancora Advisors LLC owned about 0.33% of Nutex Health worth $851,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Bank of America Corp DE raised its position in shares of Nutex Health by 6,590.3% during the 4th quarter. Bank of America Corp DE now owns 2,074 shares of the company's stock worth $66,000 after buying an additional 2,043 shares in the last quarter. OMERS ADMINISTRATION Corp grew its stake in shares of Nutex Health by 28.8% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 9,400 shares of the company's stock worth $442,000 after purchasing an additional 2,100 shares during the last quarter. Baader Bank Aktiengesellschaft grew its stake in shares of Nutex Health by 64.6% in the 1st quarter. Baader Bank Aktiengesellschaft now owns 10,700 shares of the company's stock worth $503,000 after purchasing an additional 4,200 shares during the last quarter. Northern Trust Corp acquired a new position in shares of Nutex Health in the 4th quarter worth approximately $200,000. Finally, Millennium Management LLC acquired a new position in shares of Nutex Health in the 4th quarter worth approximately $213,000. 5.32% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
NUTX has been the topic of several recent research reports. Maxim Group set a $205.00 price objective on shares of Nutex Health and gave the stock a "buy" rating in a research note on Tuesday, August 26th. Benchmark lifted their price objective on shares of Nutex Health from $150.00 to $300.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Finally, Wall Street Zen downgraded shares of Nutex Health from a "buy" rating to a "hold" rating in a research report on Friday. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $252.50.
Get Our Latest Stock Report on NUTX
Nutex Health Stock Performance
Nutex Health stock opened at $83.38 on Friday. The firm's 50 day simple moving average is $99.74 and its 200-day simple moving average is $103.61. The company has a market cap of $463.59 million, a P/E ratio of 7.01 and a beta of -0.17. The company has a debt-to-equity ratio of 1.02, a current ratio of 2.27 and a quick ratio of 2.26. Nutex Health Inc. has a fifty-two week low of $17.51 and a fifty-two week high of $184.27.
Nutex Health Profile
(
Free Report)
Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.
Featured Stories
Want to see what other hedge funds are holding NUTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nutex Health Inc. (NASDAQ:NUTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nutex Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.
While Nutex Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
